Fibrocell Science Inc (FCSC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Fibrocell Science Inc (FCSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9844
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX-013 for linear scleroderma; and a research program for the treatment of arthritis and related conditions. Fibrocell Science utilizes its proprietary autologous fibroblast technology to develop personalized biologics for skin diseases. It has a manufacturing facility in Exton, Pennsylvania; and operates along with its subsidiaries in the US and Switzerland. Fibrocell Science is headquartered in Exton, Pennsylvania, the US.

Fibrocell Science Inc (FCSC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Amends Co-Development Agreement with Intrexon 15
Licensing Agreements 16
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Equity Offering 20
Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20
Fibrocell Science Raises USD6 Million in Private Placement of Shares 22
Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23
Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26
Fibrocell Raises USD17.3 Million in Public Offering of Shares 27
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$50.5 Million 29
Fibrocell Science Completes Private Placement Of Shares For US$45 Million 31
Fibrocell Science Completes Second Tranche Of Private Placement For US$5.8 Million 33
Debt Offering 34
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34
Acquisition 35
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35
Fibrocell Science Inc – Key Competitors 36
Fibrocell Science Inc – Key Employees 37
Fibrocell Science Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Joint Venture 38
Recent Developments 39
Financial Announcements 39
Aug 09, 2018: Fibrocell Reports second quarter 2018 financial results and recent highlights 39
May 10, 2018: Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights 41
Mar 19, 2018: Fibrocell Announces 2017 Financial Results 43
Nov 13, 2017: Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights 45
Aug 09, 2017: Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights 47
May 10, 2017: Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights 48
Mar 09, 2017: Fibrocell Reports 2016 Financial Results and Recent Operational Highlights 49
Product Approvals 51
Feb 05, 2018: Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma 51
Jun 12, 2017: Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma 52
Clinical Trials 53
May 09, 2017: Fibrocell and Intrexon Announces Data on FCX-013 at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Amends Co-Development Agreement with Intrexon 15
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20
Fibrocell Science Raises USD6 Million in Private Placement of Shares 22
Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23
Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26
Fibrocell Raises USD17.3 Million in Public Offering of Shares 27
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$50.5 Million 29
Fibrocell Science Completes Private Placement Of Shares For US$45 Million 31
Fibrocell Science Completes Second Tranche Of Private Placement For US$5.8 Million 33
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35
Fibrocell Science Inc, Key Competitors 36
Fibrocell Science Inc, Key Employees 37
Fibrocell Science Inc, Subsidiaries 38
Fibrocell Science Inc, Joint Venture 38

List of Figures
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Fibrocell Science Inc (FCSC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Implanet SA (IMPL):企業の財務・戦略的SWOT分析
    Summary Implanet SA (Implanet) is a medical device company that designs, manufactures and markets orthopaedic products. The company offers spine, knee and arthroscopy products. Its spine products are used for the treatment of spinal disorders and spinal fusion surgery. Implanet offers resorbable anc …
  • PT Jakarta International Hotels & Development Tbk:企業の戦略・SWOT・財務情報
    PT Jakarta International Hotels & Development Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Jakarta International Hotels & Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Duke Energy Carolinas LLC:企業の発電所・SWOT分析2018
    Duke Energy Carolinas LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Ambry Genetics Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • ET Solar Group Corporation-エネルギー分野:企業M&A・提携分析
    Summary ET Solar Group Corporation (ET Solar) is a provider of renewable energy equipment and services. The company produces a wide variety of photovoltaic (PV) modules based on global standards such as IEC, TUV, VDE, and UL. It also provides horizontally integrated project development; finance and …
  • First Solar, Inc.:企業の戦略・SWOT・財務情報
    First Solar, Inc. - Strategy, SWOT and Corporate Finance Report Summary First Solar, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Cre8tek Ltd (FGO):石油・ガス:M&Aディール及び事業提携情報
    Summary Cre8tek Ltd (Cre8tek), formerly Marion Energy Ltd, is an oil and gas exploration and production company. The company explores, acquires, develops, produces and markets oil and gas. It has core operations in Clear Creek field located in the Uinta Basin. Cre8tek also holds interest in the addi …
  • NextEra Energy Resources LLC-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy Resources, LLC (NEER), a subsidiary of NextEra Energy, Inc., is a diversified clean energy company and is one of the largest wholesale generators of electric power in the US. The company, together with its subsidiaries owns, develops, constructs, manages and operates electrici …
  • Ceres Power Holdings plc (CWR):企業の財務・戦略的SWOT分析
    Summary Ceres Power Holdings Plc (Ceres Power) operates as an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power …
  • BioPorto AS (BIOPOR):企業の財務・戦略的SWOT分析
    BioPorto AS (BIOPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GoldStone Resources Ltd (GRL):企業の財務・戦略的SWOT分析
    Summary GoldStone Resources Ltd (GoldStone) is a mining and mineral exploration company. The company acquires, explores, develops and produces gold properties. It offers exploration projects such as Homase-Akrokeri permits, Manso Amenfi permits, Sangola permits, Oyem permits and Ngoutou permits, amo …
  • Quad/Graphics, Inc.:企業の戦略・SWOT・財務情報
    Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Keppel Corporation Limited:企業の戦略・SWOT・財務情報
    Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • InMed Pharmaceuticals Inc (IN):企業の財務・戦略的SWOT分析
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based medicines. The company's pipeline products include INM-750, INM-405, and INM-085. Its products finds applicati …
  • Vizrt Group AS.:企業の戦略的SWOT分析
    Vizrt Group AS. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Singulus Technologies AG (SNG):電力:M&Aディール及び事業提携情報
    Summary Singulus Technologies AG (Singulus Technologies) is an optical disc production line manufacturer that develops technologies for efficient and resource-conserving production processes. The company offers optical disc solutions such as blu-ray disc, CD, and DVD production equipment. Its solar …
  • Innsuites Hospitality Trust
    Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report Summary Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Telkom SA SOC Limited:企業の戦略・SWOT・財務分析
    Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BioScrip Inc (BIOS)-医療機器分野:企業M&A・提携分析
    Summary BioScrip Inc (BioScrip), formerly MIM Corp is a healthcare service provider that offers infusion care services. The hospital provides a range of infusion services, PBM services and respiratory services. Its infusion therapy services include antimicrobial drugs, factor replacement therapy for …
  • PBF Energy Inc. (PBF)-石油・ガス分野:企業M&A・提携分析
    Summary PBF Energy Inc. (PBF Energy) is an independent oil refining company. It owns and operates crude oil refineries and related facilities in the US. Its refining assets include Delaware City refinery, Delaware; Paulsboro refinery, New Jersey; Chalmette refinery, Louisiana, Torrance, California a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆